WallStreetZenWallStreetZen

NASDAQ: OKYO
Okyo Pharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for OKYO

Based on 2 analysts offering 12 month price targets for Okyo Pharma Ltd

Min Forecast
$5.00+212.5%
Avg Forecast
$6.00+275%
Max Forecast
$7.00+337.5%

Should I buy or sell OKYO stock?

Based on 2 analysts offering ratings for Okyo Pharma Ltd.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OKYO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates OKYO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their OKYO stock forecasts and price targets.

OKYO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-20
lockedlocked$00.00+00.00%2025-12-08

1 of 1

Forecast return on equity

Is OKYO forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is OKYO forecast to generate an efficient return on assets?

Company
-327.67%
Industry
31.75%
OKYO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OKYO earnings per share forecast

What is OKYO's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.35
Avg 2 year Forecast
-$0.33
Avg 3 year Forecast
-$0.40

OKYO revenue forecast

What is OKYO's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$21.2M

OKYO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OKYO$1.60$6.00+275.00%Strong Buy
ACET$6.43$63.50+887.56%Strong Buy
TCRX$1.07$6.00+460.75%Buy
DOMH$2.79N/AN/A
ICCC$6.60N/AN/A
View Top Biotech Stocks

Okyo Pharma Stock Forecast FAQ

Is Okyo Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: OKYO) stock is to Strong Buy OKYO stock.

Out of 2 analysts, 2 (100%) are recommending OKYO as a Strong Buy, 0 (0%) are recommending OKYO as a Buy, 0 (0%) are recommending OKYO as a Hold, 0 (0%) are recommending OKYO as a Sell, and 0 (0%) are recommending OKYO as a Strong Sell.

If you're new to stock investing, here's how to buy Okyo Pharma stock.

What is OKYO's earnings growth forecast for 2027-2029?

(NASDAQ: OKYO) Okyo Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.66%.

Okyo Pharma's earnings in 2026 is -$4,613,341.On average, 4 Wall Street analysts forecast OKYO's earnings for 2027 to be -$13,336,021, with the lowest OKYO earnings forecast at -$12,813,039, and the highest OKYO earnings forecast at -$13,728,257. On average, 3 Wall Street analysts forecast OKYO's earnings for 2028 to be -$12,551,549, with the lowest OKYO earnings forecast at -$12,059,331, and the highest OKYO earnings forecast at -$12,920,712.

In 2029, OKYO is forecast to generate -$15,216,446 in earnings, with the lowest earnings forecast at -$14,616,555 and the highest earnings forecast at -$15,662,518.

What is OKYO's revenue growth forecast for 2027-2029?

(NASDAQ: OKYO) Okyo Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.82%.

Okyo Pharma's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast OKYO's revenue for 2027 to be $0, with the lowest OKYO revenue forecast at $0, and the highest OKYO revenue forecast at $0. On average, 3 Wall Street analysts forecast OKYO's revenue for 2028 to be $0, with the lowest OKYO revenue forecast at $0, and the highest OKYO revenue forecast at $0.

In 2029, OKYO is forecast to generate $815,312,309 in revenue, with the lowest revenue forecast at $123,708,127 and the highest revenue forecast at $1,415,471,691.

What is OKYO's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: OKYO) forecast ROA is -327.67%, which is lower than the forecast US Biotechnology industry average of 31.75%.

What is OKYO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year OKYO price target, the average OKYO price target is $6.00, with the highest OKYO stock price forecast at $7.00 and the lowest OKYO stock price forecast at $5.00.

On average, Wall Street analysts predict that Okyo Pharma's share price could reach $6.00 by Feb 20, 2027. The average Okyo Pharma stock price prediction forecasts a potential upside of 275% from the current OKYO share price of $1.60.

What is OKYO's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: OKYO) Okyo Pharma's current Earnings Per Share (EPS) is -$0.19. On average, analysts forecast that OKYO's EPS will be -$0.35 for 2027, with the lowest EPS forecast at -$0.33, and the highest EPS forecast at -$0.36. On average, analysts forecast that OKYO's EPS will be -$0.33 for 2028, with the lowest EPS forecast at -$0.31, and the highest EPS forecast at -$0.34. In 2029, OKYO's EPS is forecast to hit -$0.40 (min: -$0.38, max: -$0.41).

What is OKYO's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: OKYO) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.